Find Your Fit: 4 New Additions to the Belkin SoundForm Audio Collection Announced at IFA 2024
5.9.2024 10:00:00 CEST | Business Wire | Press release
SoundForm offers more options for premium features at accessible price points Belkin International at Exhibit Hall 3.2, stand #210
Belkin, a leading consumer electronics brand for over 40 years, today announced 4 new products across its SoundForm audio category, underscoring Belkin innovation, quality and its commitment to building products more responsibly. Belkin International can be found on the IFA show floor, Exhibit Hall 3.2, stand #210.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240905446437/en/
Belkin announces new SoundForm portfolio at IFA 2024 (Photo: Business Wire)
Designed in its in-house labs at Belkin Global Headquarters in California, every SoundForm product undergoes 150 meticulous quality tests, ensuring perfection before it reaches consumer’s ears. Design, sound quality, comfort, voice-calling performance, enhanced features and value are all considered with each new addition to the SoundForm portfolio.
Belkin Signature Sound is integrated throughout the SoundForm range. Developed by Belkin sound engineers, it allows the wearer to listen to music exactly the way the artist intended. Deep bass is balanced, vocals are crystal-clear, and treble is crisp. To do this, Belkin sound engineers test headphone and earphone frequency response and distortion, passive noise isolation, Environmental Noise Cancellation (ENC), Active Noise Cancellation (ANC) performance, and Sound Pressure Level (SPL) to ensure proper 98db output for ‘adult’ products and 85db ‘safe sound’ for ‘kids’ products—and more. All new SoundForm products feature ENC for voice isolating clear call quality as standard.
Consumers will find a product in the SoundForm collection to suit their needs–all without breaking the bank.
SoundForm Rhythm
The SoundForm Rhythm earbuds pack a punch while taking up minimal space. They were designed for consumers looking for a casual pair of earbuds for entertainment, work/study purposes, or daily use.
Features:
- Design: True wireless, stem-shaped
- Sound: 6mm drivers
- Battery life: 8 hours with an additional 20 hours of battery life in charging case; 10 minutes of charge gets 90 minutes of playtime
- Connection: Bluetooth 5.3 and Multipoint
- Included in package: USB-C fast charging compatible case
- Built with recycled plastics and packaged in 100% plastic-free packaging
- 2-year warranty
Price: $34.99 / £24.99 / €29.99
Availability: SoundForm Rhythm is available now on belkin.com and select retailers worldwide
SoundForm ClearFit
Get a (good) grip with the SoundForm ClearFit. When it’s time to move, ClearFit is a go-to. Perfect for sports, outdoor activities and workouts, these earbuds stay comfortably secured around the outer ear for great sound while allowing the user to stay aware of their surroundings.
Features:
- Design: Open-ear, secure, comfortable and IPx5 sweat resistant
- Sound: 14.2mm drivers
- Battery life: 8 hours with an additional 18 hours of battery life in charging case; 10 minutes of charge gets 90 minutes of playtime
- Connection: Bluetooth 5.3 and Multipoint
- Included in package: USB-C fast charging compatible case
- Built with recycled plastics and packaged in 100% plastic-free packaging
- 2-year warranty
Price: $59.99 / £39.99 / €49.99
Availability: SoundForm ClearFit is available now on belkin.com/de and belkin.com/uk and select retailers worldwide
SoundForm Isolate
The SoundForm Isolate is the first over-ear headphone with ANC by Belkin. Made for the modern and stylish individual, Isolate provides quality ANC at a reasonable price point. In addition to ANC, Isolate also has a built-in “Relaxation” track that plays on a loop for moments where you need to further tune out external noise. They come with a long battery life of 60 hours, 3 settings (Standard Listening, Active Noise Cancellation, Hear Thru Mode) and Bluetooth multipoint – all in a sleek and portable design.
Features:
- Design: Over-ear, foldable, extendable and comfortable with 5 mics and intuitive touch controls to easily manage sound with a tap
- Sound: 40mm drivers
- Battery life: 60 hours of battery life (40 hours with ANC on)
- Connection: Bluetooth 5.4 and Multipoint
- Included in package: USB-C charging and audio cable; 3.5mm audio cable for users that prefer wired connection
- Built with recycled plastics and packaged in 100% plastic-free packaging
- 2-year warranty
Price: $59.99 / £49.99 / €59.99
Availability: SoundForm Isolate will be available from Autumn 2024
SoundForm Surround
The SoundForm Surround over-ear headphones are perfect for when you need to chat on the go. ENC ensures clear calls with background noise kept to a whisper. Its foldable, extendable, and comfortable over-ear design and intuitive touch controls make SoundForm Surround an everyday accessory.
Features:
- Design: Over-ear, foldable, extendable and comfortable with intuitive touch controls to easily manage sound with a tap
- Sound: 40mm drivers
- Battery life: 60 hours
- Connection: Bluetooth 5.4 and Multipoint
- Included in package: USB-C charging and audio cable; 3.5mm audio cable for users that prefer wired connection
- Built with recycled plastics and packaged in 100% plastic-free packaging
- 2-year warranty
Price: $39.99 / £29.99 / €39.99
Availability: SoundForm Surround will be available from Autumn 2024
All new products are made with post-consumer recycled (PCR) plastics in line with the company’s commitment to find more responsible ways to build products. They will be on display at IFA 2024.
Media kit is available for download HERE.
About Belkin
Belkin is a California-based accessories leader delivering award-winning power, protection, productivity, connectivity, and audio products over the last 40 years. Designed and engineered in Southern California and sold in more than 100 countries around the world, Belkin has maintained its steadfast focus on research and development, community, education, sustainability and most importantly, the people it serves. From our humble beginnings in a Southern California garage in 1983, Belkin has become a diverse, global technology company. We remain forever inspired by the planet we live on, and the connection between people and technology.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240905446437/en/
Contacts
For Media Inquiries:
For Media Inquiries:
Jen Wei
VP of Global Communications and Corporate Development
Comms@belkin.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom